It is reported by RIA Novosti.
“The study was based on an analysis of data from 3,591 medical students fully vaccinated with Sputnik V, AstraZeneca, Sinopharm, India's Bharat Biotech and Iran's COVIran Barrekat between March and August 2021.
According to the results of the study, Sputnik V demonstrated the best results in protection against coronavirus infection after vaccination,” the RDIF said.
They noted that the proportion of participants who fell ill with COVID-19 was 3.13 of the total number vaccinated with the Russian drug (Sinopharm - 4.23%, AstraZeneca - 6.22%).
“A previously unique independent study in Hungary comparing directly five coronavirus vaccines (Sputnik V, Moderna, Pfizer-BioNTech, Sinopharm and AstraZeneca) based on data from 3.7 million people between January and June 2021 demonstrated that “ Sputnik V has the best protection rate against deaths from coronavirus at 98% and an efficiency of 85.7% against coronavirus infection,” the fund noted.
RDIF is the main investor in the development and production of the Sputnik V and Sputnik Light vaccines.
Sputnik V is approved for use in 71 countries, Sputnik Light is approved for use in more than 30 countries.